Fresenius Announces Apollo Database Project to Glean Clinical Insights From 540,000 Dialysis Patients
Fresenius Medical Care, a leader in manufacturing and selling dialysis equipment, has announced the completion of phase one of its Apollo database project. This anonymized global dialysis dataset, the largest multinational, longitudinal database of its kind, marks an important step in Fresenius Medical Care’s long-term AI strategy and ongoing digital transformation efforts. The Apollo database offers a comprehensive view into the clinical care of over 540,000 dialysis patients. The company plans to use AI analysis of this cloud-based database to drive improvements in care quality and patient outcomes. The database has data from 40 countries across six continents, comprises over 350 patient treatment parameters, data from more than 540,000 dialysis patients, 140 million dialysis treatments, and 34 million laboratory assessments. The database is powered by Fresenius’s network of 4,050 dialysis clinics that serve 344,000 patients globally.
Fresenius Medical Care plans to showcase research presentations using the new database at the American Society of Nephrology Kidney Week conference taking place from November 2 to 5 in Philadelphia, Pennsylvania. Currently, the project powers over 15 clinical improvement initiatives, including a global feasibility assessment of expanding the use of an Anemia Control Model—an AI model used in multiple countries to optimize erythropoietin stimulating agents and iron therapies in dialysis patients.
Stuart McGuigan, Global Chief Information Officer of Fresenius Medical Care, highlighted the company’s digital transformation and the Apollo Database project as crucial milestones in both the digital evolution and long-term AI strategy of the organization. The project represents a substantial leap in harnessing data generated across the company’s global clinical footprint, underscoring its competitive advantage.